top of page

Opdivo (nivolumab)

Price

$200.00

TYPE OF PURCHASE:

IMPORTANT NOTE

PHARMALERT does NOT sell medical treatments

SERVICE DESCRIPTION

  • A one-time report on the current approval and market dominance status in dozens of markets across all regions, OR
  • E-mail alerts over a 6-month period about worldwide regulatory approvals of the originator drug and first-mover competitors

⁤

​
bottom of page